Cancer cell and Fas ligand (CD95 ligand): Immune escape or self-attack

Pediatric Pathology and Molecular Medicine

Volumn 19, Issue 4, 2000, Pages 223-234

  Uckan, D ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Cancer; CD95; Fas; Immune; Tumor

Indexed keywords

FAS ANTIGEN; LIGAND;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CARCINOGENESIS; CELL DEATH; CELL INTERACTION; CELL SURVIVAL; CROSS LINKING; DNA DAMAGE; DNA REPLICATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; T LYMPHOCYTE ACTIVATION; TROPHOBLAST;

EID: 0033793054     PISSN: 15227952     EISSN: None     Source Type: Journal    
DOI: 10.1080/pdp.19.4.223.234     Document Type: Article

References (62)

1. Normal cells and cancer cells
2. Apoptosis and carcinogenesis
3. A matter of life and cell death
4. Apoptosis and drug response
5. The molecular pathogenesis of cancer
6. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
7. The Fas counterattack: Fasmediated cell killing by colon cancer cells expressing Fas ligand
8. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells
9. Life (and death) in a malignant tumor
10. The clinical significance of Fas expression in leukemia: Questions and controversies
11. The Fas death factor
12. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
13. Expression of Fas ligand by human gastric adenocarcinomas: A potential mechanism of immune escape in stomach cancer
14. Immune escape mechanisms in Hodgkin's disease
15. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
16. Human melanoma cells do not express Fas (Apo-1/Cd95)ligand
17. Tumor expression of Fas ligand (CD95L) and the consequences
18. Fas and Fas ligand interactions suppress melanoma lung metastasis
19. Fas and FasL in the homeostatic regulation of immune responses
20. Fas and Fas ligand: 1pr and gld mutations
21. Fas-FasL interactions: A common pathogenetic mechanism in organ-specific autoimmunity
22. Fas ligand-induced apoptosis as a mechanism of immune-privilege
23. A role for CD95 ligand in preventing graft rejection
24. Trophoblasts express Fas ligand: A proposed mechanism for immune privilege in placenta and maternal invasion
25. The immunology of pregnancy
26. Immune privilege: Keeping an eye on natural killer T cells
27. Resistance to tolerance induction is not prerequisite to development of murine SLE
28. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
29. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
30. Arousal and inhibition of human NK cells
31. Natural killer cells: From no receptors to too many
32. The CTL's kiss of death
33. Caspase dependence of target cell damage induced by cytotoxic lymphocytes
34. Autocrine and paracrine apoptosis are mediated by differential regulation of Fas ligand activity in two distinct Jurkat cell populations
35. Expression of the functional soluble form of human Fas ligand in activated lymphocytes
36. Fas ligand in human serum
37. Fas (CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection
38. Cell death induced by the Fas/2Fas ligand pathway and its role in pathology
39. Fas ligand: A sensor for DNA damage critical in skin cancer etiology
40. Death receptors: Signaling and modulation
41. Caspases: Enemies within
42. Identification of a new caspase homologue: Caspase-14
43. Caspase activation is required for nitric-oxide-mediated, CD95(APO-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells
44. Mitochondrial control of apoptosis
45. Mitochondria and apoptosis
46. The Bcl-2 protein family: Arbiters of cell survival
47. Increased apoptosis of T cell subsets in aging humans: Altered expression of Fas (CD95), Fas ligand, Bcl-2, and Bax
48. The tumor suppressor genes and their mechanisms of action
49. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes
50. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway
51. FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis
52. The biochemical mechanisms of oncogene action
53. Controlling the cellular brakes
54. Uterine cell death during implantation and early placentation
55. C-myc and tumor suppressor gene product expression in developing and term human trophoblast
56. Human trophoblast-endometrial interactions in an in vitro suspension culture system
57. CD44 in human placenta. Localization and binding to hyaluronic acid
58. Fasmediated induction of hepatocyte apoptosis in a neuroblastoma and hepatocyte coculture model
59. Molecular genetics in the management of patients with cancer
60. Immunotoxins and recombinant toxins in the treatment of solid carcinomas
61. Inhibition of tumor cell invasion by a highly conserved peptide sequence form the matrix metalloproteinase enzyme prosegment
62. Demonstration of a rationale strategy for human prostate cancer gene therapy